We read with a great interest the paper focused on different minimal residual disease (MRD) approaches and its significance in Ph+ acute lymphoblastic leukemia (ALL) patients, authored by Short et al. from the MD Anderson Cancer Center. We would like to thank the authors for this important data, and offer a short comment from our pediatric experience.